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Introduction: Previous cancer-associated germline mutation studies have highlighted tumor 
suppressor genes such as TP53, APC, BRCA2, NF1, PMS2, and RB1. Many studies on tumor 
suppressor genes have been conducted because of the high penetration rate of pathogenic 
mutations. For this reason, cancer-related germline studies have been focused on tumor 
suppressor genes, and the role of germline genes other than tumor suppressor genes remains 
unclear. However, the possibility of presenting non-tumor suppressor genes that affect tumor 
development is not negligible. The mechanism of tumorigenesis by these non-tumor suppressor 
genes that exist as germline mutations contribute differently to tumor development. In this study, 
we will discuss the relationship between two different types of non-tumor suppressor genes and 
tumorigenesis. The first is the germline mutation of oncogenes in Acute Myeloid Leukemia(AML) 
patients, and the second is the correlation between primary immunodeficiency-associated gene 
mutations and tumor risk. 
 
Methods: To determine the oncogenic germline mutation of AML, WES data of 76 individuals 
from Seoul National University were analyzed. The correlation between immunodeficiency 
disease and cancer development was assessed using ICGC WGS data from 2566 individuals. For 
the normal control, WGS data of 2504 individuals were obtained from the 1000 Genome Project, 
and tumor susceptibility was examined by comparing the cancer and control groups.  
 
Results: We focused on the germline FLT3 as an oncogenic gene that increases the incidence of 
AML. An FLT3 germline mutation in four loci was identified in 76 patients with AML, and the 
cancer incidence was confirmed to increase in the locus corresponding to D358V. The overall 
survival of patients with D358V was significantly decreased, indicating that the mutation had a 
negative effect on the prognosis of patients. 
Regarding the association between PID and cancer, it has been confirmed that the PID-related 
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genes increase cancer risk by 1.5 fold. Seven carcinomas were also associated with increased 
cancer risk, and the age of onset was significantly reduced in hepatocellular carcinoma and 
bladder cancer patients with PID. 
 
Conclusions: We revealed the association between two germline mutations and increased cancer 
risk, which was previously undefined owing to the rare frequency. The first germline mutation 
gene was the FLT3 mutation known as the oncogene. FLT3, which exists as a germline mutation, 
is presumed to contribute to the development of tumor cells by reducing FLT3 activity and turning 
on alternative cell signal transduction, unlike the FLT3 somatic mutation that induces cell division 
of tumor cells. The second germline mutation is a primary immunodeficiency disease-associated 
gene. Loss-of-function in immunodeficiency-associated genes does not directly induce cancer 
development but is assumed to promote tumorigenesis owing to a diminished immune 
surveillance effect. In addition to germline factors identified in this study, more novel germline 
factors are expected to be revealed. These efforts will contribute to the development of 
prophylactic treatments to prevent cancer patients from experiencing a relapse after treatment. 
------------------------------------- 
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The “two-hit” hypothesis of Alfred Knudson began to identify cancer 
predisposition genes (CPGs), which are associated with an increased risk of 
cancer germline mutations (Rahman, 2014). Through a statistical analysis of 
retinoblastoma cases, Knudson proposed that “two hits” to the DNA were 
necessary to cause cancer. The “first hit” is an inherited variation in one 
allele of the gene while the “second hit” is a somatically acquired 
inactivation of the second allele (Knudson, 1971). This model was confirmed 
by the identification of biallelic inactivation of the RB1 gene in 
retinoblastoma, and most known high-penetrance inherited cancer 
predisposition variants are loss-of-function mutations in recessively acting 
tumor suppressor (TS) genes (Knudson, 2001; Rahman, 2014). 
Additionally, previous pan-cancer studies have highlighted pathogenic 
germline variants in tumor suppressor genes, including ATM, BRCA1, 
BRCA2, BRIP1, and PALB2 in adult cancer cases recorded in The Cancer 
Genome Atlas (TCGA) (Lu et al., 2015) and the Collaborative Oncological 
Gene-Environment Study (COGS) (Southey et al., 2016), as well as TP53, 
APC, BRCA2, NF1, PMS2, and RB1 using 1,120 pediatric cancer cases from 
the Pediatric Cancer Genome Project (PCGP) (Zhang et al., 2016).  
Along with this historical background, the study of the interaction between 
genes, other than tumor suppressor genes, and cancer risk has not been 
investigated. In this paper, we discuss the relationship between two types of 
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germline mutations and cancer risk in addition to tumor suppressor genes, 
which have gone unnoticed in the past. 
The first type of germline mutation is the oncogenes mutation in cancer 
patients. Despite a close correlation between gene function and cancer 
development, epidemiologic studies have not recognized the oncogene as a 
germline mutation that increases cancer risk. However, HRAS, EGFR, and 
KIT genes that increase tumor susceptibility to rhabdomyosarcoma, ganglion 
cell tumor, and bladder cancer were reported as oncogene-predisposing 
germline mutations (Aoki et al., 2005; Centeno et al., 2011; Hirota et al., 
2002). This phenomenon supports the assumption that other oncogenic genes 
may be present.  
The second type of germline mutation is the development of tumors due 
to the haploinsufficiency phenomenon, especially the reduction of immune 
surveillance as a result of the dysfunction of primary immunodeficiency 
disease-associated genes. In the case of primary immunodeficiency disease 
(PID), the direct association between PID and cancer development was not 
known, so it was not considered as a germline factor. However, the 
association between various severe PIDs and cancer was revealed through 
epidemiological analysis of the multicenter registry of patients with PID 
(Kersey et al., 1974; Mayor et al., 2018; Rodrigues et al., 2004).  
These germline factors are evolutionarily at a very low frequency in the 
general population even though they are relevant to the disease, so it is 
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difficult to determine their relationship with cancer development. However, 
the past decade has seen an exponential increase in the number of genomic 
data, enabling researchers to discover germline factors that were previously 
hidden. Based on this trend, we made an effort to reveal novel germline 
factors and will present our results in this paper as follows: 1) Germline 
mutations of FLT3 that are associated with increased cancer risk and poor 
prognosis in acute myeloid leukemia (AML) patients; 2) Primary 
immunodeficiency disease and cancer risk using the Korean AML cohort 
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The idea that cancer is formed through the accumulation of multiple genetic alterations 
is known as the two-hit or multiple-hit hypothesis. Carl O. Nordling first proposed the 
multiple-hit hypothesis in 1953 (Nordling, 1953) when he suggested that multiple hits to 
DNA were necessary to cause cancer. Genetic alternation can be a combination of 
multiple somatic pathogenic variants or a combination of somatic and germline 
pathogenic variants. Traditionally, somatic pathogenic variants have received the majority 
of research focus, and few studies have investigated the role of germline pathogenic 
variants. 
Acute myeloid leukemia (AML) is a form of cancer characterized by infiltration of the 
bone marrow, blood, and other tissues by proliferative, clonal, and abnormally 
differentiated cells of the hematopoietic system (Dohner et al., 2015). Conventionally, the 
French-American-British (FAB) classification has been used to classify AML. The FAB 
classification is based on cell morphology and not disease mechanism; therefore, it is 
difficult to predict prognosis and select optimal therapeutic approaches for AML using 
this classification system. As a result, pathogenic variants in several genes, including 
FLT3, RUNX1, PMA-RARA, and NPM1, which have been repeatedly observed in AML, 
are used in disease classification. Of these pathogenic variants, those affecting FLT3 
(FMS-Like Tyrosine Kinase 3, also known as FLK2 [fetal liver kinase 2] and STK1 
[human stem cell tyrosine kinase 1]), which plays a key role in hematopoiesis and 
leukemogenesis are some of the most important in AML. Although many AML patients 
achieve complete remission (CR) with conventional induction chemotherapy, a 
significant proportion of patients experience a relapse, and relapse rates are significantly 
higher in patients with pathogenic variants (Abu-Duhier et al., 2001; Dohner et al., 2010; 
Fathi and Chen, 2011; Frohling et al., 2002; Gilliland and Griffin, 2002; Levis et al., 2002; 
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Levis and Small, 2003; Nakao et al., 1996). Consequently, FLT3 pathogenic variants are 
often associated with poor disease prognosis, and it is recommended that AML therapy 
be specified according to the patients’ pathogenic variant status (O'Donnell et al., 2011).  
Despite the role of FLT3 in hematopoiesis and its association with poor prognosis, the 
complete clinical implications of germline pathogenic variants have not been clearly 
shown.  
Here we demonstrate that the germline FLT3 pathogenic variant is strongly associated 
with AML development and prognosis. We suggest that in addition to the somatic 
pathogenic variant, the germline pathogenic variant is a significant genetic factor 
affecting AML prognosis. In particular, the p.D358V pathogenic variant and the 
prognosis of AML patients were first reported in this study. This is a valuable finding to 





MATERIALS AND METHODS 
IRB approval 
A total of 76 AML patients were enrolled in this study, and bone marrow and saliva 
samples were obtained from these patients. This study was approved by the Seoul 
National University Hospital Institutional Review Board (IRB approval number: 1201-
099-396). 
 
Sample preparation and DNA extraction 
Human genomic DNA was extracted from saliva and bone marrow using the QuickGene 




We sequenced exomes from genomic DNA using the Solexa sequencing technology 
platform (HiSeq 2000, Illumina, San Diego, CA, USA) following the manufacturer’s 
instructions. Briefly, we randomly aliquoted 3 µg of genomic DNA using the Covaris 
System to generate about 150 bp inserts. The fragmented DNA was end-repaired using 
T4 DNA polymerase and Klenow polymerase, and Illumina paired-end adaptor 
oligonucleotides were ligated to the sticky ends. We analyzed the ligation mixture using 
agarose gel electrophoresis and purified fragments between 200 and 250 bp in size. To 
capture 50-Mb targeted exons, the purified DNA library was hybridized with the 
SureSelect Human All Exon V3 and V5 probe set (Agilent, Santa Clara, CA, USA) 
following the manufacturer’s instructions. This captured exome library was then 





Exome sequencing data analysis and validation through genotyping  
We aligned the FASTQ sequence files to the human reference (human_g1k_v 37.fasta) 
using the Burrows-Wheeler Aligner (Li and Durbin, 2009) (BWA-0.7.5), producing a 
single SAM file. We converted the SAM file to BAM format using SortSam in Picard-
tools-1.68. We then used chromosome sorting and marked PCR duplicates using Picard 
to eliminate the duplicates from subsequent analysis with the Genome Analysis Toolkit 
(GATK-1.6.5) (McKenna et al., 2010b). To identify germline and somatic pathogenic 
variants in the FLT3 gene (chr13:28578189-28674647), we utilized the Haplotypecaller 
tool on GATK and the Broad Institute’s MuTect, respectively. Functional annotation was 
performed using ANNOVAR (Wang et al., 2010), and we predicted the functional effect 
of germline pathogenic variants using Polyphen-2 (Adzhubei et al., 2013).  
To validate our results, we genotyped the SNP rs34172843 (Thermo Fisher Scientific, 
South San Francisco, CA) in a total of 64 AML patients using a TaqMan assay (Livak, 
1999). Briefly, approximately 20 ng of purified genomic DNA was added to a genotyping 
mixture consisting of 2X genotyping master mix, 20X SNP genotyping assay, DNase-free 
water, and template DNA, followed by a 40-cycle PCR reaction. Amplicons were 
analyzed using the ABI PRISM 7900 HT Sequence Detection System (Applied 
Biosystems, Foster City, CA). Genotyping quality control was performed in 10% of the 
samples by assessing the concordance rate between duplicates (> 99.5%). 
 
Characterization of D358V pathogenic variants in The Cancer Genome Atlas 
(TCGA) data set  
Approval for access to the International Cancer Genome Consortium’s (ICGC) Cancer 
Genome Atlas and clinical data was obtained as a Pan-Cancer Analysis of Whole 
Genomes (PCAWG) researcher (DACO-1063499). To analyze the distribution of 
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clinically significant D358V germline pathogenic variants in TCGA, SNP calling variant 
call format (VCF) files were downloaded from the National Cancer Institute (NCI) sftp 
server (sftp://dccsftp.nci.nih.gov). A total of 2,834 SNP VCF from patients with 41 cancer 
types were selected for further analysis. The somatic pathogenic variant profile of D358V 
pathogenic variants in TCGA was obtained from the cBioPortal database 
(http://cbioportal.org) 
 
Comparison with normal population  
To analyze the significance of FLT3 germline pathogenic variants in AML, we compared 
the 76 AML patients recruited for this study with 2,504 individuals from the 1,000 
Genomes Project (http://www.internationalgenome.org). Genotype information was 
extracted using tabix-0.2.6 (Li, 2011).  
 
Statistical analysis  
AML patients were classified according to the FAB classification system. Risk groups 
based on cytogenetic and molecular analyses of bone marrow samples were determined 
using the Medical Research Council (MRC) criteria (Grimwade et al., 2010). Patient 
demographic information and survival outcomes were obtained from medical records. 
Overall survival (OS) was defined as the duration from diagnosis to death from any cause, 
and relapse-free survival (RFS) was defined as the time from diagnosis until relapse or 
death from any cause. Living patients were censored at the date of the last contact. 
Kaplan-Meier plots were constructed to determine the clinical significance of D358V 




Distribution of germline and somatic FLT3 pathogenic variants in AML patients  
To assess the distribution of germline and somatic FLT3 pathogenic variants, we 
evaluated matched saliva and bone marrow samples from the 76 patients in our cohort 
using exome sequencing. Germline pathogenic variants were assessed from saliva 
samples, and somatic pathogenic variants were assessed in bone marrow tumor samples. 
The average patient age was 46 years, with 61% male and 39% female (Table 1-1). 
We identified a total of four germline mutation loci on chromosome 13: 28624294, 
28674628, 28622544, and 28608473. All of the mutations were not found in the tyrosine 
kinase domain; see Fig 1A. The most abundant germline pathogenic variant was p.T227M 
(chr13:28624294) found in 55 (72.3%) patients. The next most frequent pathogenic 
variant was p.D7G (chr13:28674628) found in 16 (19.7%) patients, followed by p.D358V 
(chr13:28622544) in 6 (7.8%) patients and p.V557I (chr13:28608473) in 1.3% of patients 















Table 1-1. Patient demographics 

































(N=76) (N=6) (N=70) 
Gender, N (%)    
  Male 47 (61) 6 (100) 39 (55) 
  Female 29 (39) 0 (0) 31 (45) 
Age (average) 46 58 45 
FAB classification, 
N (%) 
   
  AML-ET 1 (1) 0 (0) 1 (1) 
  AML-MDS 9 (12) 3 (50) 6 (8) 
  AML-MPD 1 (1) 0 (0) 1 (1) 
  M0 2 (3) 0 (0) 2 (3) 
  M1 7 (9) 0 (0) 7 (9) 
  M2 22 (29) 1 (17) 21 (30) 
  M3 13 (17) 2 (33) 11 (16) 
  M4 12 (16) 0 (0) 12 (16) 
  M5 3 (4) 0 (0) 3 (4) 
  Unknown 6 (8) 0 (0) 6 (8) 
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Risk Group, N (%)    
  Adverse 23 (30.2) 3 (50) 20 (28.5) 
  Intermediate 21 (27.6) 1 (16.6) 20 (28.5) 
  Favorable 31 (40.7) 2 (33.3) 29 (41.4) 





































FLT3 T227M MISSENSE 13 28624294 G A rs1933437   55 21   734 60   0.21 <0.001  0.004 
FLT3 D7G MISSENSE 13 28674628 T C No rsID   15 61   410 384   0.23 <0.001  0.451 




FLT3 V557I MISSENSE 13 28608473 C T rs35958982   1 75   4 790   2.62 0.36  0 
 




 Two specific regions on the FLT3 locus (p.D835V/H and p.D358V) 
were affected by somatic pathogenic variants (Fig 2). One pathogenic 
variant, in the p.D835 region, affected the FLT3 tyrosine kinase domain, 
a frequently mutated locus in AML (Sheikhha et al., 2003). Two patients 
carried a p.D835 somatic pathogenic variant (p.D835V and p.D835H). A 
third pathogenic variant, p.D358V, affecting the FLT3 immunoglobulin 
domain, was detected in a single patient. Unlike p.D835 pathogenic 
variants, p.D358V pathogenic variants are not well described in AML.  
According to TCGA, the p.D358V somatic pathogenic variant is not 
reported for several other cancer types in addition to AML (Fig 1B). 
Interestingly, as described above, this locus was observed not only as a 
somatic pathogenic variant but also as a germline pathogenic variant in 
our AML cohort. Using polyphen-2 (Adzhubei et al., 2013) to predict the 
functional effect of the pathogenic variant, we determined that D358V is 










Figure 1-1. Distribution of FLT3 somatic and germline pathogenic 
variants 
Each bar represents a genetic variation. A) is germline pathogenic variant 
information which is observed in Korean AML patients. B) is somatic 
pathogenic variant patterns of the FLT3 gene in The Cancer Genome 
Atlas (TCGA) data. Each bar represents a somatic pathogenic variant and 
the length of the bar means the number of pathogenic variants. The color 
of the bar indicates the type of pathogenic variant: the green color is the 
missense pathogenic variant; the black is the truncating pathogenic 
variant; the brown is the in-frame pathogenic variant; and the purple is 
the splicing region of the pathogenic variant. The D358V pathogenic 
variant was not reported in the TCGA database.  
Figure 1-2. FLT3 pathogenic variant characteristics 
A plot is showing the pathogenic variant pattern of the FLT3 gene 
screened in the Korean AML cohort. The blue marker is a patient with a 
somatic pathogenic variant, and the green marker is a patient with a 
germline pathogenic variant. Pathogenic variants at the 358 amino acid 
position of the FLT3 gene (D358V) were found both as somatic 
















Prevalence and ethnic specificity of FLT3 germline p.D358V 
pathogenic variants in AML 
To determine whether FLT3 germline pathogenic variants are 
associated with a predisposition to developing AML, we compared the 
frequency of FLT3 germline pathogenic variants in our cohort to that of 
FLT3 germline pathogenic variants among 754 members of the normal 
Asian population segment of the 1000 Genomes Project (n=794). The 
frequency of the p.D358V pathogenic variant was significantly higher 
(p=4.0E-02 and OR=2.63) in AML patients than in the general 
population, suggesting that a predisposition to AML development is 
associated, at least in part, with the FLT3 germline pathogenic variant. 
In contrast, the T227M and D7G germline pathogenic variants were 
significantly higher in the normal Asian population (OR=0.21, p<0.001 
and OR=0.23, p<0.001) than in AML patients. No significant difference 
in frequency was observed for the V557I (p=0.36) or pathogenic variants 
(Table 1-2) between AML patients and members of the general 
population. 
 
Distribution of the p.D358V pathogenic variant in The Cancer 
Genome Atlas 
To determine the distribution of the p.D358V FLT3 pathogenic variant 
in TCGA, we collected a total of 834 SNP VCF called by the DFKZ 
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calling pipeline in 2,834 patients with 41 different types of cancer. We 
identified the p.D358V pathogenic variant in ten patients with five 
cancers: a US population with ovarian serous cystadenocarcinoma, a 
German population with pediatric brain cancer, a Japanese population 
with liver cancer, a Korean population with acute myeloid leukemia, and 
a Chinese population with gastric cancer. The p.D358V had the highest 
observed frequency in the Japanese liver cancer cohort (2.4%; 6 of 250 
patients).  
 
Clinical implications of the p.D358V germline pathogenic variant  
We classified AML patients, according to the FAB classification and 
determined risk groups using the MRC criteria. The most common FAB 
classification subtype was M2 (22%), and most patients were classified 
into the favorable risk group (40.7%). There were no significant 
differences in clinical characteristics between the two groups.  
Overall survival was significantly reduced in patients with the p.D358V 
pathogenic variant (p=0.03 by log-rank test; see Fig 3A). Disease-free 
survival also decreased, though the difference was not significant 
(p=0.52 by log-rank test).  
To further assess the prognostic value of p.D358V in AML, we 
investigated the correlation between p.D358V and survival outcomes in 
the Japanese liver cancer cohort from TCGA. The overall survival of 
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liver cancer patients was significantly reduced in patients with p.D358V 
(p=0.03; see Fig 3B), suggesting that the p.D358V germline pathogenic 
variant affects prognosis across several cancer types. The association 
between FLT3 and liver cancer is not well known, but records from the 
cBioPortal database indicated twelve of 1,115 patients (1.1%) with 
hepatocellular carcinoma had FLT3 mutations. Interestingly, seven of 
them were truncation mutations that lost FLT3 gene function, suggesting 
that the loss-of-function of FLT3 would benefit liver cancer cell growth. 
The overall survival of patients with hepatocellular carcinoma was 
significantly reduced (p=0.01; see Figure 1-4) in patients with the FLT3 
mutation, similar to the outcome of patients with D358V.  
In summary, the decreased activity of the FLT3 gene may be beneficial 





Figure 1-3. Clinical significance of the germline FLT3 D358V 
pathogenic variant 
Prognosis of patients according to D358V genetic variation: (+) is the 
overall survival of patients with genetic pathogenic variants, and (-) is 
the overall survival of patients without genetic pathogenic variants. A) is 
the overall survival for the liver cancer cohort of the AML cohort and B) 
is that for the ICGC data set. 
 
Figure 1-4. Clinical significance of the FLT3 somatic mutation in 
liver cancer  
Cases with alterations are shown with a red line. On the other hand, cases 
without alterations are shown with a blue line. 
 
Figure 1-5. White blood cell count according to the FLT3 D358V 
pathogenic variant  
Each dot represents a white blood cell count from an individual patient. 
White blood cell counts are compared between patients with and without 














In general, patients with TKD pathogenic variants or ITD pathogenic 
variants, which are a functional gain of the FLT3 gene, have higher white 
blood cell counts compared to normal individuals. To estimate how the 
p.D358V pathogenic variant plays a role in the activity of the FLT3 gene, 
we compared the white blood cell counts between patients with the 
pathogenic variant and without the pathogenic variant. Comparing white 
blood cell counts at the time of diagnosis with gene activity (How et al., 
2012) revealed no difference in white blood cell counts between patients 
with or without the p.D358V germline pathogenic variant; however, the 
white blood cell count had a tendency to decrease in patients with 
p.D358V, implying that this pathogenic variant induces low gene activity 






AML-specific FLT3 pathogenic variants have been an intense research 
focus over the past few decades. The effects of somatic pathogenic 
variants, which usually present as the highly prevalent activating 
pathogenic variants such as FLT3 TKD or FLT3 ITD, are well 
understood. In contrast, the effect of germline FLT3 pathogenic variants 
remains largely unknown, as does their impact on prognosis. Here, while 
screening a Korean AML cohort, we found an enrichment in a three 
germline FLT3 pathogenic variants (p.D358V, p.T227M, and p.D7G). 
Although the presence of two alleles (T227M and D7G) was related to a 
reduction in the risk for AML (P<0.001, respectively), the clinical 
significance was not confirmed in this cohort. Nielka P et al. reported 
that the presence of the p.T227M allele reduced the risk of leukopenia, 
but the clinical effect of the mutation was not assessed. In addition, 
p.D7G was identified in CML patients with BCR-ABL fusion but not 
biochemically characterized; thus, the effects on FLT3 protein function 
were not yet known (Lyu et al., 2016; van Erp et al., 2009). In contrast, 
the p.D358V pathogenic variant was associated with poor disease 
prognosis. 
Germline pathogenic variants of tyrosine kinase receptors such as KIT 
or EGFR have been reported to contribute to tumorigenesis in other 
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cancers (Centeno et al., 2011; Hirota et al., 2002). An FLT3 germline 
variant (R387Q) was identified to have an overlapping somatic 
pathogenic variant in endometrial cancer (Lu et al., 2015). Most 
pathogenic variants affecting tyrosine kinase receptors such as KIT, 
EGFR, and FLT3 are known to induce tumors by increasing gene activity 
through self-activation or by disabling gene regulation [24-26]. In 
contrast, Sandhofer et al. suggested that the loss-of-function phenotype 
of the p.Q569Vfs pathogenic variant may induce cell proliferation in 
AML by activating alternative cell-signaling independent of activity [27]. 
It was out of the scope of our work to elucidate the biological 
significance of the FLT3 p.D358V germline pathogenic variant we 
identified in AML patients. The pathogenic variant does not alter the 
white blood cell count significantly; however, it tends to reduce white 
blood cell counts. In addition, we confirmed through in silico analysis 
that the pathogenic variant blocks FLT3 enzyme activity, which supports 
the finding that this variant affects low gene activity. While we cannot 
exclude the possibility that the p.D358V pathogenic variant is a natural 
single nucleotide polymorphism with no influence on leukemogenesis, it 
is important to note that germline pathogenic variants in the same locus 
have been detected repetitively in tumor cells. Thus, we can infer that 
this pathogenic variant facilitates the growth of leukemia cells by 
escaping FLT3-mediated regulation of cell growth.  
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To elucidate the mechanism of receptor interaction with the p.D358V 
pathogenic variant, functional characterization of the FLT3 pathogenic 
variant is critical. We found that FLT3 pathogenic variants did not always 
activate the gene; therefore, we recommend that the functional 
characteristics of FLT3 pathogenic variants should be investigated 
individually. While such analyses were outside of the scope of this study, 
we provide an important description of the FLT3 germline pathogenic 
variant and report for the first time the association between the p.D358V 
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Immune deficiency diseases, which are associated with immune system 
failure, are classified into two main groups. Primary immunodeficiency 
diseases (PID) are caused by congenital genetic disorders, whereas 
secondary immunodeficiency diseases (SID) result from acquired factors, 
such as human immunodeficiency virus (HIV) infection or organ 
transplants. 
 Due to the abnormal function of the immune system, patients 
with both types of immunodeficiency exhibit various clinical symptoms, 
including persistent or recurring infections, auto-inflammatory disorders, 
tumors, and disorders of various organs. Among these symptoms, tumor 
cell development results from the suppression of immune surveillance. 
The theory of immune surveillance states that the immune system is 
constantly monitoring the presence of cancerous cells, and in most cases, 
it will destroy these abnormal cells. However, in patients with decreased 
immune surveillance activity due to PID or SID, abnormal cells can 
escape and proliferate to produce tumors. The association between 
cancer development and decreased immune surveillance function has 
been well-established, and several immunodeficiency diseases are 
known to increase cancer incidence. Thus, there is strong 
epidemiological evidence for the role of immune surveillance in cancer 
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prevention, as evidenced by the increased risk of cancers detected among 
specific immunocompromised patients (Mayor et al., 2018). In particular, 
various cancers often occur in patients with acquired immunodeficiency 
syndrome (AIDS) due to HIV infection. Some of the most common 
carcinomas associated with AIDS include non-Hodgkin lymphoma, 
Kaposi’s sarcoma, and cervical cancer (Yarchoan and Uldrick, 2018).  
An increased risk of secondary solid cancers among allogeneic 
hematopoietic cell transplant (HCT) recipients is also well-documented. 
HCT recipients have significantly higher than expected rates of invasive 
solid cancers, such as oral cavity, esophageal, lung, soft tissue, and brain 
cancer (Majhail et al., 2011). In addition, solid organ transplant recipients 
have elevated risks for cancer development due to both 
immunosuppression and oncogenic viral infections. Thus, recipients of a 
kidney, liver, heart, or lung transplant experience higher rates of a diverse 
array of infection-related and unrelated cancers, as compared with the 
general population (Engels et al., 2011). 
Unlike SIDs, which arise due to external influences, such as 
infection or transplantation, PIDs are caused by a defect in various genes. 
As with SIDs, an association between PIDs and various cancers has been 
noted for decades (Filipovich et al., 1992; Hayward et al., 1997; Mayor 
et al., 2018). The increased cancer incidence observed in PID patients 
has been studied using a multi-center registry of subjects that focuses on 
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those with clinically overt immunodeficiency. This cohort mostly 
includes patients with diseases that are epidemiologically classified as 
autosomal recessive, which implies a loss-of-function due to the double 
allele defect.  
However, some of the patients in this study were diagnosed with 
an autosomal dominant form of PID. The main cause of this phenomenon 
is known as haploinsufficiency, which was first reported in 1989 for a 
condition called angioedema (Ariga et al., 1989). Haploinsufficiency 
refers to the occurrence of a particular mutant phenotype in 
heterozygotes, despite a lack of negative dominance of the mutant allele 
over its wild-type (WT) counterpart. Genes with haploinsufficiency 
show incomplete penetrance when considering the predicted 50% 
residual function of the gene product (Rieux-Laucat and Casanova, 
2014). Thus, phenotypes can range from mild to moderate, depending on 
the extent of gene penetration, and this can result in the presence of 
heterozygous carriers with mild traits in the normal population. Critically, 
in these individuals, the altered function of the mutated gene may impair 
cellular homeostasis and promote abnormal cell growth, which can 
increase cancer risk. 
This phenomenon was noted in a previous study that revealed a 
correlation between heterozygous carrier status for lysosomal storage 
disease (LSD) and cancer (Shin et al., 2018). Notably, the risk of cancer 
39 
 
was found to be significantly increased in heterozygous carriers of 42 
LSD-related gene variants. Importantly, this study was possible through 
two international collaborative studies, the International Cancer Genome 
Consortium (ICGC) and the 1000 Genomes Project, both of which 
produced large-scale whole genome sequencing (WGS) data. These two 
datasets contain genetic information from unrelated adult individuals 
without severe pediatric disease, whose genomes were sequenced as part 
of various cancer-specific and population genetic studies. Therefore, 
pathogenic variants identified from these studies are considered to have 
a low penetration of Mendelian disease, and correlations can be 
estimated by comparing the variant distribution between the two datasets. 
In this study, we hypothesize that in mild carriers of PID-
associated alleles, the accumulation of abnormal cells, which are not 
adequately removed by defective immune surveillance mechanisms in 
these individuals, results in increased risk for the development of 
malignant cancer. Here we report a comprehensive analysis of the pan-
cancer association for putative pathogenic germline mutations in 114 
PID-related genes using data from the ICGC and the 1000 Genomes 
Project. Our data indicate an increased risk for the development of 
certain cancers in carriers of pathogenic gene variants. Moreover, the 
reliability of this phenomenon was confirmed by validating this result in 
an external cohort.  
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MATERIALS AND METHODS 
Study cohort 
We used two large whole genome databases, each containing a subset of 
donors who were not diagnosed with immunodeficiency disease until 
they reached adulthood. The ICGC dataset contains genetic information 
from 2,566 individuals with cancer (Pan-Cancer cohort), and the control 
dataset from the 1000 Genomes Project (1000 Genomes cohort) is 
comprised of 2,504 genomes (The Genomes Project, 2015). 
A total of 1,667 patients, who were diagnosed with bladder 
cancer (n=530), liver cancer (n=465), hematology cancer (n=297), or 
stomach cancer (n=375), was used as an external validation cohort for 
target sequencing. Recruitment for the external validation cohort of this 
study was approved by the Seoul National University Hospital 
Institutional Review Board (IRB approval number: 1805-067-946).  
 
Putative pathogenic variant selection (PPV) 
After an extensive literature review, we identified 114 PID-related genes 
(Table 2-1). First of all, we identified a truncated mutation which was 
expected to cause functional deleterious substitution (Stop-gain/loss, 
Start-loss, Splice site) and frameshift indel. We then screened curated 
disease databases, including the Human Gene Mutation Database 
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Professional 2018.2 (HGMD) and ClinVar, for pathogenic variants with 
possible deleterious function. In this way, we identified putative disease-
causing variants that present strong evidence for functional 
deleteriousness. Based on the evidence that most allele frequencies (AF) 
for pathogenic variants in the clinical database are less than 0.1%, we 
excluded all variants with mean AFs (arithmetic means of the Pan-
Cancer and 1000 Genomes cohorts) >0.1% from the putative pathogenic 
variant (PPV) selection process (Figure 2-1). An overall flow chart for 






Figure 2-1. The Exome Aggregation Consortium (ExAC) allele 
frequencies for pathogenic variants of PID-related genes identified 
in the ClinVar and HGMD databases  
The ExAC allele frequencies of variants described as pathogenic 
mutations in 114 PID-related genes are divided into five ranges, and the 
number of variants in each range is plotted. 
 
Figure 2-2. Overall flow chart for our PPV selection method 
 
Table 2-1. The 114 genes associated with primary 














Gene Phenotype Inheritance Classification 
DOCK8 Hyper-IgE recurrent infection syndrome Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
IRF7 Immunodeficiency 39 Autosomal Recessive Defects in intrinsic and innate immunity 
ELANE Neutropenia Autosomal Dominant Congenital defects of phagocyte 
ISG15 Immunodeficiency 38 Autosomal Recessive Defects in intrinsic and innate immunity 
TNFRSF4 Immunodeficiency 16 Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
TERT Pulmonary fibrosis and/or bone marrow failure Autosomal Dominant CID with associated or syndromic features 
CD81 Immunodeficiency 6 Autosomal Recessive Predominantly antibody deficiencies 
CARD11 
B-cell expansion with NFκB and T-cell anergy,  
immunodeficiency 11A, immunodeficiency 11B with atopic dermatitis  
Autosomal Dominant Predominantly antibody deficiencies 
TRNT1 
retinitis pigmentosa, and erythrocytic microcytosis,  
Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and 
developmental delay 
Autosomal Recessive Predominantly antibody deficiencies 
MEFV Familial Mediterranean fever Autosomal Dominant Undefined 
STIM1 Immunodeficiency 10 Autosomal Recessive CID with associated or syndromic features 
CD27 Lymphoproliferative syndrome 2 Autosomal Recessive Diseases of immune dysregulation 
AICDA Immunodeficiency with hyper-IgM Autosomal Recessive Predominantly antibody deficiencies 
PIK3CD Immunodeficiency 14 Autosomal Dominant Predominantly antibody deficiencies 
IL17RC Candidiasis Autosomal Recessive Defects in intrinsic and innate immunity 
TYK2 Immunodeficiency 35 Autosomal Recessive Defects in intrinsic and innate immunity 
PARN Dyskeratosis congenita, pulmonary fibrosis and/or bone marrow failure Autosomal Dominant CID with associated or syndromic features 
DCLRE1C Omenn syndrome, severe combined immunodeficiency Autosomal Recessive 




TNFRSF13B Immunodeficiency 2 Autosomal Recessive Predominantly antibody deficiencies 
IL17RA Immunodeficiency 51 Autosomal Recessive Defects in intrinsic and innate immunity 
JAK3 Severe combined immunodeficiency Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
IL12RB1 Immunodeficiency 30 Autosomal Recessive Defects in intrinsic and innate immunity 
RFXANK MHC class II deficiency Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
PNP Immunodeficiency due to purine nucleoside phosphorylase deficiency Autosomal Recessive CID with associated or syndromic features 
IGLL1 Agammaglobulinemia 2 Autosomal Recessive Predominantly antibody deficiencies 
TINF2 Dyskeratosis congenita, Revesz syndrome Autosomal Dominant CID with associated or syndromic features 
FOXN1 T-cell immunodeficiency, congenital alopecia, and nail dystrophy Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
UNC119 Immunodeficiency 13 Autosomal Dominant 
Immunodeficiencies affecting cellular and 
humoral immunity 
IL21R Immunodeficiency 56 Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
EXTL3 Immunoskeletal dysplasia with neurodevelopmental abnormalities Autosomal Recessive CID with associated or syndromic features 
CD19 Immunodeficiency, common variable, 3 Autosomal Recessive Predominantly antibody deficiencies 
LAT Immunodeficiency 52 Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
CORO1A Immunodeficiency 8 Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
TCN2 Transcobalamin II deficiency Autosomal Recessive CID with associated or syndromic features 
DNMT3B Immunodeficiency-centromeric instability-facial anomalies syndrome 1 Autosomal Recessive CID with associated or syndromic features 
LCK Immunodeficiency 22 Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
TAP2 Bare lymphocyte syndrome, type I Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
TAP1 Bare lymphocyte syndrome, type I Autosomal Recessive 




TAPBP Bare lymphocyte syndrome, type I Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
IFNAR2 Immunodeficiency 45 Autosomal Recessive Defects in intrinsic and innate immunity 
NOP10 Dyskeratosis congenita, autosomal recessive 1 Autosomal Recessive CID with associated or syndromic features 
IFNGR2 Immunodeficiency 28, mycobacteriosis Autosomal Recessive Defects in intrinsic and innate immunity 
IL7R 
Severe combined immunodeficiency, T-cell negative, B-cell/natural killer-
cell positive type 
Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
NFKBIA Ectodermal dysplasia and immunodeficiency Autosomal Dominant CID with associated or syndromic features 
RAG2 
Combined cellular and humoral immune defects with granulomas,  
Omenn syndrome, severe combined immunodeficiency, B-cell negative 
Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
CSF3R Neutropenia, severe congenital, 7, autosomal recessive Autosomal Recessive Congenital defects of phagocyte 
NCF4 
Granulomatous disease, chronic, autosomal recessive, cytochrome b-
positive, type III 
Autosomal Recessive Congenital defects of phagocyte 
RAC2 Neutrophil immunodeficiency syndrome Not Determined Congenital defects of phagocyte 
MYD88 Pyogenic bacterial infections Not Determined Defects in intrinsic and innate immunity 
RHOH Epidermodysplasia verruciformis Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
STAT5B Growth hormone insensitivity with immunodeficiency Not Determined CID with associated or syndromic features 
CTPS1 Immunodeficiency 24 Autosomal Recessive Diseases of immune dysregulation 
IKBKB Immunodeficiency 15A, immunodeficiency 15B Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
G6PC3 Dursun syndrome, neutropenia, severe congenital 4 Autosomal Recessive Congenital defects of phagocyte 
TNFRSF13C Immunodeficiency, common variable, 4 Autosomal Recessive Predominantly antibody deficiencies 
ADA Severe combined immunodeficiency Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
EPG5 Vici syndrome Autosomal Recessive CID with associated or syndromic features 
IRAK4 Invasive pneumococcal disease, recurrent isolated, 1 Not Determined Defects in intrinsic and innate immunity 
RELB Immunodeficiency 53 Autosomal Recessive 




BLOC1S6 Hermansky-Pudlak syndrome 9 Autosomal Recessive CID with associated or syndromic features 
ITGB2 Leukocyte adhesion deficiency Autosomal Recessive Congenital defects of phagocyte 
TTC7A Gastrointestinal defects and immunodeficiency syndrome Autosomal Recessive CID with associated or syndromic features 
PRKDC Immunodeficiency 26 Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
IKZF1 Immunodeficiency, common variable, 13 Autosomal Dominant Predominantly antibody deficiencies 
IL17F Candidiasis Autosomal Dominant Defects in intrinsic and innate immunity 
RAB27A Griscelli syndrome, type 2 Autosomal Recessive Diseases of immune dysregulation 
MALT1 Immunodeficiency 12 Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
STAT2 Immunodeficiency 44 Autosomal Recessive Defects in intrinsic and innate immunity 
MS4A1 Immunodeficiency, common variable, 5 Autosomal Recessive Predominantly antibody deficiencies 
CD79B Agammaglobulinemia 6 Autosomal Recessive Predominantly antibody deficiencies 
RTEL1 Dyskeratosis congenita Autosomal Dominant CID with associated or syndromic features 
FERMT3 Leukocyte adhesion deficiency, type III Autosomal Recessive Congenital defects of phagocyte 
PIK3R1 Agammaglobulinemia 7, immunodeficiency 36, SHORT syndrome Autosomal Recessive Predominantly antibody deficiencies 
AP3B1 Hermansky-Pudlak syndrome 2 Autosomal Recessive Diseases of immune dysregulation 
PGM3 Immunodeficiency 23 Autosomal Recessive CID with associated or syndromic features 
BCL10 Immunodeficiency 37 Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
IRF8 
Immunodeficiency 32A, mycobacteriosis,  
immunodeficiency 32B, monocyte and dendritic cell deficiency 
Autosomal Recessive Defects in intrinsic and innate immunity 
CD8A CD8 deficiency Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
CYBA Chronic granulomatous disease Autosomal Recessive Congenital defects of phagocyte 
NBN Nijmegen breakage syndrome Autosomal Recessive CID with associated or syndromic features 
GFI1 Neutropenia, severe congenital 2 Autosomal Dominant Congenital defects of phagocyte 
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HELLS Immunodeficiency-centromeric instability-facial anomalies syndrome 4 Autosomal Recessive CID with associated or syndromic features 
BLNK Agammaglobulinemia 4 Autosomal Recessive Predominantly antibody deficiencies 
BCL11B Immunodeficiency 49 Autosomal Dominant 
Immunodeficiencies affecting cellular and 
humoral immunity 
NFKB1 Immunodeficiency, common variable, 12 Autosomal Dominant Predominantly antibody deficiencies 
NFKB2 Immunodeficiency, common variable, 10 Autosomal Dominant Predominantly antibody deficiencies 
ATM Ataxia-telangiectasia Autosomal Recessive CID with associated or syndromic features 
UNG Immunodeficiency with hyper-IgM, type 5 Autosomal Recessive Predominantly antibody deficiencies 
CD3E Immunodeficiency 18 Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
CD3D Immunodeficiency 19 Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
CD3G Immunodeficiency 17, CD3 gamma-deficient Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
ORAI1 Immunodeficiency 9, myopathy, tubular aggregate, 2 Autosomal Dominant CID with associated or syndromic features 
IL21 Immunodeficiency, common variable, 11 Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
GATA2 Emberger syndrome, immunodeficiency 21 Autosomal Dominant Congenital defects of phagocyte 
POLE FILS syndrome Autosomal Recessive CID with associated or syndromic features 
IFNGR1 Immunodeficiency 27A/B, mycobacteriosis Autosomal Recessive Defects in intrinsic and innate immunity 
CARD9 Candidiasis Autosomal Recessive Congenital defects of phagocyte 
VPS45 Neutropenia, severe congenital 5 Autosomal Recessive Congenital defects of phagocyte 
RFX5 Bare lymphocyte syndrome, type II, complementation group C/E Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
HAX1 Neutropenia, severe congenital 3 Autosomal Recessive Congenital defects of phagocyte 
ITK Lymphoproliferative syndrome 1 Autosomal Recessive Diseases of immune dysregulation 
FCGR3A Immunodeficiency 20 Autosomal Recessive Defects in intrinsic and innate immunity 
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CD247 Immunodeficiency 25 Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
DOCK2 Immunodeficiency 40 Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
CDCA7 Immunodeficiency-centromeric instability-facial anomalies syndrome 3 Autosomal Recessive CID with associated or syndromic features 
WIPF1 Wiskott-Aldrich syndrome 2 Not Determined CID with associated or syndromic features 
NHP2 Dyskeratosis congenita, autosomal recessive 2 Autosomal Recessive CID with associated or syndromic features 
NCF2 Chronic granulomatous disease due to deficiency of NCF-2 Autosomal Recessive Congenital defects of phagocyte 
STAT1 Immunodeficiency 31A, immunodeficiency 31B, immunodeficiency 31C Autosomal Dominant Defects in intrinsic and innate immunity 
PTPRC 
Severe combined immunodeficiency, 
 T-cell negative, B-cell/natural killer-cell positive 
Autosomal Recessive 
Immunodeficiencies affecting cellular and 
humoral immunity 
CR2 Immunodeficiency, common variable, 7 Autosomal Recessive Predominantly antibody deficiencies 
NHEJ1 
Severe combined immunodeficiency with microcephaly, 
growth retardation, and sensitivity to ionizing radiation 
Not Determined 
Immunodeficiencies affecting cellular and 
humoral immunity 
SP110 Hepatic venoocclusive disease with immunodeficiency Autosomal Recessive CID with associated or syndromic features 
LYST Chediak-Higashi syndrome Autosomal Recessive Diseases of immune dysregulation 




Adjustment for population structure differences 
Principal component analysis (PCA) was performed using the individual 
genotypes of tag single-nucleotide polymorphisms (tag-SNPs), which 
represent the population-distinguishing linkage disequilibrium blocks. 
We identified a total of 1,555,886 candidates for tag-SNPs from MAP 
and PED files that were downloaded from the phase 3 HapMap ftp server 
(ftp://ftp.ncbi.nlm.nih.gov/hapmap/phase_3/). We then converted the 
genomic positions of these tag-SNPs to GRCh37/hg19 coordinates using 
the Batch Coordinate Conversion (liftOver) tool, created by the UCSC 
Genome Browser Group (https://genome.ucsc.edu/cgi-bin/hgLiftOver). 
 The Genome Analysis Toolkit was used to merge VCF files from 
the Pan-Cancer and 1000 Genomes cohorts (McKenna et al., 2010a), and 
tag-SNPs with AFs ≥5% and ≤50% were extracted from merged VCF 
files using VCFtools, version 1.13, resulting in 16,304 filtered tag-SNPs 
(Danecek et al., 2011). Among these, population-stratifying tag-SNPs 
were selected using the PLINK pruning method (Purcell et al., 2007), 
thereby reducing linkage disequilibrium panels containing a number of 
SNPs to a condensed subset of representative tag-SNPs (Novembre et al., 
2008). As a result, 10,494 tag-SNPs were selected for use in the 




Figure 2-3. PC1 and PC2 values generated from PCA analysis using 
tag-SNPs from the Pan-Cancer and 1000 Genomes cohorts  
Subjects are classified into four groups based on ethnicity: African 
(AFR), East Asian (ASN), South Asian (SAN), and European/American 
(EUR/AMR), and the PC1 and PC2 values for each group are compared. 
These values reflect genetic differences in the four groups and validate 







The Pan-Cancer and 1000 Genomes cohorts were analyzed using the 
SKAT-O test for rare-variant association, the Fisher Exact test, and 
logistic regression for direct comparison of mutation prevalence (Lee et 
al., 2012). We also adjusted for population structure using PCA on the 
10,494 filtered tag-SNPs (Figure 2-3). Wilcoxon rank-sum tests and 
logistic regression were performed for between-group comparisons of 
age, and CIBERSORT was used for immune cell milieu analysis (Chen 
et al., 2018).  
Correction for multiple testing was conducted using the false 
discovery rate (FDR) estimation procedure, and the tail area-based FDR 
was reported (Benjamini et al., 2001). All tests were two-tailed unless 
otherwise specified. We considered an FDR <0.1 or P-value <0.05 (when 
not adjusted for multiple testing) to be statistically significant. 
Identification of differentially expressed genes (DEGs) and gene set 
analysis were performed using the DESeq2 (Love et al., 2014) 
Bioconductor package and bioinformatics enrichment tools (Huang da et 
al., 2009), based on the framework of the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathway maps (Kanehisa and Goto, 2000), R 
version 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria), 
in combination with pipelines from Bioconductor version 3.5, were used 
for all analyses.  
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Mutation signature analysis 
Statistical comparison of mutational load (logistic regression) between 
PPV-bearing and PPV-free tumors for each mutational signature showed 
no significant results at a threshold of P<0.05. Data used in this analysis 
were from the official beta version of mutational signatures for single 
nucleotide substitutions generated and uploaded to the SFTP server 
(sftp://dccsftp.nci.nih.gov/pancan/) by the Pan-Cancer Analysis of 
Whole Genomes Project team in March 2017. 
 
Target sequencing for validation 
DNA was extracted from 400 μl of blood or buffy coat using the Exgene 
Blood SV kit (GeneAll Biotechnology, Seoul, Korea). DNA samples 
(500 ng) were then sheared into 250–300 bp fragments with a Q800R3 
Sonicator (Qsonica, Newtown, CT, USA). The ACCEL-NGS 2S DNA 
Library Kit was used to create index-ligated libraries according to the 
LIBRARY KITS (Swift Biosciences, Ann Arbor, MI, USA) protocol, 
and the dsDNA library concentrations were measured with the Qubit 
dsDNA HS Assay kit (Thermo Fisher Scientific, Waltham, MA, USA). 
Ten libraries containing 150-ng DNA per sample were pooled and 
subjected to hybridization according to the xGen hybridization capture 
DNA libraries (IDT) protocol. Briefly, xGen Lockdown Probes (43 genes 
or 144 genes) were incubated at 65°C for 4 or 16 hours, and streptavidin 
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beads were used for capture. Samples were sequenced using an Illumina 




Description of study cohorts 
The Pan-Cancer cohort is comprised of four ethnic populations and 38 
histological subtypes of pediatric or adult cancer. We graphed the 
population distribution of this cohort, as well as the control 1000 
Genomes cohort for comparison, and found that EUR/AMR was the 
most common ethnicity in the Pan-Cancer ICGC cohort (Figure 2-4). 
The 1000 Genomes normal control cohort is comprised of four ethnic 
classifications, with EUR/AMR being the most prevalent (The Genomes 
Project, 2015).  
 
PPV prevalence in the Pan-Cancer and 1000 Genomes cohorts 
For the 114 PID-associated genes, we identified 36,292 germline single 
nucleotide variants (SNVs) and small insertions and deletions (indels) in 
the variant call sets of the Pan-Cancer and 1000 Genomes cohorts. Of 
these, 502 PPVs were defined through the selection process described 
above. The overall distribution of PPV carriers among cancer patients 
was 13.6%, whereas the distribution of PPV carriers in normal controls 
was 8.5%. This is statistically significant after adjusting for population 
structure (Odds ratio [OR]: 1.8, confidence interval [CI]: 1.5–2.2) 
(Figure 2-5). Conversely, we detected no difference in the distribution of 
58 
 
synonymous variants that do not result in functional changes, thus 
confirming that the PPV distribution in the two groups was not due to 
chance or structural bias.  
Across the 30 major histological subtypes (each with >15 
individuals per subtype), PPV prevalence ranged from 5.5% to 33.3%, 
and for seven of these, the PPV prevalence was significantly higher than 
that in the 1000 Genomes cohort. These were bladder cancer (21.7%), 
breast adenocarcinoma (13.3%), liver cancer (13.0%), chronic 
lymphocytic leukemia (CLL; 17.7%), pancreas adenocarcinoma (17.6%), 
pancreas endocrine (24.6%), and soft tissue leiomyoma (33.3%).  
 We then classified the 114 PID genes into seven categories based 
on the immunological symptoms of their associated disease (Bousfiha et 
al., 2018; Machet, 1998) (Figure 2-6) and determined the PPV 
prevalence for each group in the two cohorts. Among these seven 
classifications, PPV enrichment in five (i.e., Diseases of immune 
dysregulation, Congenital defects of phagocytes, Immunodeficiencies 
affecting cellular and humoral immunity, Predominantly antibody 
deficiencies, and Combined immunodeficiency disease (CID) with 
associated or syndromic features) was significantly associated with 
increased cancer incidence (Figure 2-7-a). The highest frequency 
classification was “CID with associated or syndromic features.” We 
performed clustering analysis using the frequency of PPV in each 
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histology type. Clustering analysis of the PPV distribution pattern for 
each disease classification further revealed dominant patterns of PPV 
enrichment in “CID with associated or syndromic features” and 




Figure 2-4. Demographics of the study cohorts  
The pie chart on the left is a representation of the percentage of 
ethnographic classifications for each of the two cohorts. The 2,566 
subjects from the ICGC (Pan-Cancer) cohort are shown on the upper left, 
and the 2,504 individuals from the 1000 Genomes cohort are on the 
lower left. The right bar chart indicates the ethnicity information for each 
histological subtype in the ICGC cohort. 
 
Figure 2-5. Comparison of PPV prevalence in each cohort  
The bar chart on the left shows PPV frequency for the 114 PID-
associated genes in the Pan-Cancer (ICGC) and control 1000 Genomes 
(TG) cohorts. The right bar chart shows the odds ratios (ORs) calculated 
from the comparison between each histological subtype and TG. P-
values were calculated by logistic regression and are expressed in 
different colors: grey >0.05, yellow <0.05, orange <0.01, and red <0.001.  
 
Figure 2-6. Functional classification of the diseases associated with 
the 114 PID genes  
The chart on the left shows the distribution ratios for the 114 PID genes 
within the seven immune classifications. Additional information on the 
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subclasses (not including “undefined”) is listed on the right. 
 
Figure 2-7. Comparison of PPV prevalence within each functional 
classification  
a) A comparison of PPV prevalence within the seven immune 
classifications of the Pan-Cancer (ICGC) and 1000 Genomes (1000G) 
cohorts is shown. The top graph shows the odds ratios (ORs) for each 
classification, with the frequencies graphed below. b) A clustering 
analysis based on the PPV frequency within the seven classifications is 
shown. Scaled values are expressed for each histological subtype. Red is 




















Association between PPV-carrier status and histological specificity 
We then measured the association between each histological subtype and 
PPV-carrier status for each of the 114 PID genes and found that 82 
cancer-gene pairs were significantly associated by SKAT-O analysis, as 
adjusted for the population structure (FDR<0.1) (Figure 2-8 and Table 2-
2). Overall, 27 histological subclasses were significantly associated with 
at least one gene, whereas 59 PID genes were associated with at least one 
cancer type. The PPV prevalence in gene-histology pairs ranged from 
0.3% to 8.6%, and the pair with the highest prevalence was the 
TNFRSF13B gene in bladder cancer. 
 
Age of cancer onset according to PPV-carrier status 
To better understand the effects of PID on cancer development, we next 
compared the age of cancer onset according to PPV-carrier status. We 
found that 18 histological subtypes showed a tendency toward decreased 
age of onset associated with PPV-carrier status. Of these, PPV carriers 
showed a significantly reduced onset age for bladder cancer (median age, 
49 vs. 69 years; P=0.002 by a one-sided test) and liver cancer (median 
age, 60 vs. 66 years; P=0.002) (Figure 2-9-a).  
The liver cancer groups within the ICGC include the US project, 
LIHC-US, which is mostly composed of non-viral hepatocellular 
carcinoma, and the Japanese project, LIRI-JP, which is primarily 
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composed of viral hepatocellular carcinoma. Interestingly, a more 
significant association between PPV-carrier status and reduced onset age 
was obtained for the LIRI-JP cohort (P-value for viral-associated 
hepatocellular carcinoma = 0.02; P-value for non-viral-associated 
hepatocellular carcinoma = 0.18; Figure 2-9-b). Among viral-associated 
hepatocellular carcinoma, the hepatitis B virus (HBV) tended to promote 
an earlier onset than the hepatitis C virus (HCV).  
The LIRI-JP cohort obtained from Japanese patients is composed 
primarily of virus-related liver cancer patients and has the largest 
composition with a homogeneous dataset. We therefore focused on this 
cohort for further analysis, as it is optimized to observe PID-related 
carcinogenesis mechanisms and to better detect the association between 
PID and virus-related cancer. 
An analysis of single gene effects revealed that PPVs in MEFV 
and TNFRSF13B were significantly associated with reduced age of onset 
for liver and bladder cancer, respectively. When the PID genes were 
classified by associated immune pathology, PPV carriers in the 
“Predominantly antibody deficiencies” category showed a significantly 
decreased age of onset for both liver and bladder cancer, whereas those 
in “CID with associated or syndromic features” and “undefined” showed 




Figure 2-8. Association between each histological subtype and PPV-
carrier status for each of the 144 PIDD genes  
The association for each gene-histology pair is represented by the dot 
plot of the false discovery rate (FDR), calculated by the SKAT-O test. 
The size of the dot is the number of patients with the gene, and the color 
of the dot is assigned to the degree of –log (FDR). 
 
Table 2-2. Statistically significant gene-histology pairs determined 
by the SKAT-O test 
 
Figure 2-9. Association between the age of cancer onset and PPV-
carrier status  
A box plot comparing the age of cancer onset for PPV carriers vs. non-
carriers is shown. The P-values at the top of the figure are calculated 
from the one-sided Wilcoxon test, and those shown in red are statistically 
significant: a) age of onset in PPV carriers vs. non-carriers for each 
histological subtype and b) age of onset in PPV carriers vs. non-carriers 
for individual liver cancer groups within the Pan-Cancer ICGC cohort.  
 
Figure 2-10. Association between the age of onset for liver and 
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bladder cancer and PPV-carrier status within individual PID genes 
and immune pathology classifications  
The ages of onset for liver and bladder cancer, which are significantly 
different, are compared in PPV carriers vs. non-carriers, both within 
specific genes and in the six groups of genes classified by immune 
pathology: a) age of onset analysis for liver cancer and b) age of onset 














Bladder-TCC TNFRSF13B 8.70% 1.01E-07 1.40E-05 
Lung-AdenoCA ATM 8.11% 0.001607895 0.066654538 
Breast-LobularCA FERMT3 7.69% 1.29E-13 4.19E-11 
Cervix-SCC TYK2 5.56% 2.95E-08 4.72E-06 
Cervix-SCC TNFRSF13B 5.56% 3.18E-05 0.002413713 
CNS-Oligo ATM 5.56% 6.25E-16 2.85E-13 
Uterus-AdenoCA MEFV 4.55% 9.95E-06 0.000934283 
CNS-PiloAstro ATM 4.49% 0.000271845 0.015223307 
Bladder-TCC IRF7 4.35% 7.85E-10 1.67E-07 
Bladder-TCC IL17RC 4.35% 2.75E-07 3.66E-05 
Bladder-TCC ATM 4.35% 0.001091647 0.049964896 
Myeloid-MPN DOCK8 3.85% 2.09E-06 0.000247526 
Myeloid-MPN POLE 3.85% 0.002503399 0.097449371 
Stomach-AdenoCA ATM 2.94% 0.000426883 0.022710185 
Biliary-AdenoCA MEFV 2.94% 0.000198147 0.011294361 
Biliary-AdenoCA IRAK4 2.94% 0.000970871 0.046254018 
Biliary-AdenoCA NBN 2.94% 0.000445182 0.0232807 
Biliary-AdenoCA ITK 2.94% 1.03E-08 1.74E-06 
Lymph-BNHL TNFRSF13B 2.80% 0.001787898 0.072240139 
Lung-AdenoCA IRF7 2.70% 4.45E-06 0.000473124 
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Lung-AdenoCA MS4A1 2.70% 0.001325167 0.057119366 
Lung-AdenoCA GATA2 2.70% 4.19E-16 2.23E-13 
CNS-GBM TRNT1 2.56% 2.24E-05 0.001886752 
CNS-GBM WIPF1 2.56% 0.000513326 0.026008518 
Panc-Endocrine CD8A 2.47% 0.000452194 0.0232807 
Kidney-ChRCC STAT5B 2.33% 0.000118396 0.007558378 
Kidney-ChRCC BLNK 2.33% 0.002107285 0.08408067 
Kidney-ChRCC CD3E 2.33% 2.58E-05 0.002112589 
Kidney-ChRCC CD247 2.33% 0.000128486 0.007748592 
Uterus-AdenoCA ELANE 2.27% 9.40E-05 0.006252993 
CNS-PiloAstro TYK2 2.25% 0.000150757 0.008911435 
Lung-SCC RELB 2.13% 0.000128658 0.007748592 
Thy-AdenoCA IFNAR2 2.08% 4.48E-05 0.003175047 
Thy-AdenoCA IL17F 2.08% 4.55E-14 1.82E-11 
Thy-AdenoCA CD3G 2.08% 0.001195804 0.053013966 
Thy-AdenoCA CR2 2.08% 8.51E-06 0.000848979 
Thy-AdenoCA NHEJ1 2.08% 1.10E-06 0.000134487 
ColoRect-AdenoCA DCLRE1C 1.92% 2.97E-09 5.58E-07 
ColoRect-AdenoCA IL7R 1.92% 0.00053281 0.026573918 
ColoRect-AdenoCA CSF3R 1.92% 9.38E-06 0.000906992 
ColoRect-AdenoCA ADA 1.92% 9.40E-08 1.36E-05 
Head-SCC CD27 1.79% 4.12E-35 4.38E-32 
Head-SCC CTPS1 1.79% 0.00134209 0.057119366 
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Head-SCC ORAI1 1.79% 3.04E-05 0.002413713 
Head-SCC SP110 1.79% 9.61E-19 6.14E-16 
Stomach-AdenoCA STIM1 1.47% 1.36E-05 0.001241944 
Stomach-AdenoCA IGLL1 1.47% 0.000121142 0.007582037 
Stomach-AdenoCA RAC2 1.47% 8.21E-12 2.02E-09 
Stomach-AdenoCA EPG5 1.47% 0.001746323 0.071464917 
Stomach-AdenoCA HELLS 1.47% 3.81E-05 0.002764214 
Stomach-AdenoCA GATA2 1.47% 1.36E-09 2.72E-07 
Stomach-AdenoCA IFNGR1 1.47% 0.000311018 0.017116722 
Panc-Endocrine IRF7 1.23% 0.00011124 0.007246515 
Panc-Endocrine TERT 1.23% 0.000665792 0.032200112 
Panc-Endocrine CD81 1.23% 6.69E-05 0.004541857 
Panc-Endocrine JAK3 1.23% 3.77E-09 6.69E-07 
Panc-Endocrine TAP2 1.23% 0.000423051 0.022710185 
Panc-Endocrine TAPBP 1.23% 0.001095721 0.049964896 
Panc-Endocrine TNFRSF13C 1.23% 5.38E-05 0.003733931 
CNS-PiloAstro LCK 1.12% 3.68E-05 0.002734566 
Lymph-CLL CARD11 1.11% 0.000574474 0.028211096 
Lymph-CLL RAB27A 1.11% 6.22E-06 0.000640147 
Eso-AdenoCA FOXN1 1.03% 0.000154431 0.008962622 
Eso-AdenoCA UNC119 1.03% 0.001176755 0.052904256 
Eso-AdenoCA FERMT3 1.03% 3.15E-05 0.002413713 
Breast-AdenoCA IRF7 1.03% 2.25E-05 0.001886752 
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Breast-AdenoCA IFNAR2 1.03% 0.002452815 0.096659073 
Skin-Melanoma IL17RA 0.93% 5.39E-140 1.72E-136 
Ovary-AdenoCA TERT 0.91% 3.26E-06 0.000358403 
Ovary-AdenoCA TYK2 0.91% 6.48E-07 8.28E-05 
Ovary-AdenoCA RELB 0.91% 0.001579269 0.066329296 
Ovary-AdenoCA DOCK2 0.91% 3.87E-46 6.18E-43 
Panc-AdenoCA AICDA 0.86% 1.51E-05 0.001336515 
CNS-Medullo CD27 0.71% 9.05E-11 2.06E-08 
CNS-Medullo ITK 0.71% 0.00102491 0.048110478 
CNS-Medullo NCF2 0.71% 6.78E-20 5.41E-17 
Kidney-RCC ELANE 0.70% 7.06E-08 1.07E-05 
Kidney-RCC LYST 0.70% 0.001266786 0.055391501 
Breast-AdenoCA CR2 0.51% 4.90E-12 1.30E-09 
Panc-AdenoCA IGLL1 0.43% 3.24E-06 0.000358403 
Liver-HCC DCLRE1C 0.32% 1.31E-13 4.19E-11 






















Influence of DNA/RNA profiles and the immune cell milieu on PPV-
bearing hepatocellular carcinoma and bladder cancer 
Based on the promising results obtained from our genetic and clinical 
analyses, we focused on hepatocellular carcinoma and bladder cancer to 
determine whether PPV-bearing and PPV-free tumors show 
differentiating patterns in somatic mutations and gene expression. We 
therefore conducted RNA sequencing (RNA-seq) and identified a total 
of 604 genes that are differentially expressed in PPV-free and PPV-
bearing hepatocellular carcinomas by DESeq2. These genes can be 
assigned to eight KEGG pathways, four of which are associated with 
cancer. In the case of bladder cancer, 1,433 genes were differentially 
expressed in PPV-free and PPV-bearing tumors, which are associated 
with 31 KEGG pathways (Figure 2-11-a,b). Somatic mutation profiles 
and signature analyses were also determined to further elucidate the basis 
for these observed differences in gene expression; however, no distinct 
signatures or mutation profiles were detected in either carcinoma (Figure 
2-12).  
Based on our finding that virus-associated hepatocellular 
carcinoma is more strongly associated with PPV-carrier status, we 
analyzed the immune cell milieu in this cancer subtype. Specifically, we 
measured the distribution of 22 types of immune cells infiltrating into 
the liver tissues using whole transcript sequencing in PPV carriers vs. 
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non-carriers. We found significant differences in two types of immune 
cells based on PPV-carrier status. That is, the infiltration of follicular 
helper T cells (Tfh) was significantly decreased in PPV carriers (P=0.04), 
whereas infiltration of regulatory T cells (Treg) was significantly 
increased in cancer tissues of PPV carriers (P=0.02) (Figure 2-13-a,b).  
 
Family history of PPV-carrier status 
To investigate the possibility that PPVs associated with PID are inherited 
from parents as germline factors, we examined family liver cancer 
history. We hypothesized that if PPVs inherited from parents affect 
cancer development, the parents of the cancer patients with PPVs should 
have a higher cancer risk, as compared to parents of the cancer patients 
without PPVs. Consistent with this, family history analysis revealed that 
parents of HCV-related liver cancer patients with PPVs had a 5.87-fold 
higher family history of cancer than parents of HCV liver cancer patients 




Figure 2-11. Analysis of differentially expressed genes (DEGs) from liver and bladder cancer in PPV carriers vs. 
non-carriers  
Hierarchical clustering of DEGs and gene set enrichment analysis from a) liver cancer and b) bladder cancer. 
 
Figure 2-12. Mutation signature analysis  
For each sample, the number of mutations corresponding to each signature is plotted. Orange bars indicate PPV 
carriers and green bars indicate non-carriers. 
 
Figure 2-13. Infiltrating immune cell milieu in virus-related hepatocellular carcinoma from PPV carriers and 
non-carriers  
Analysis of the immune cell milieu infiltrating into the liver tissue in subjects with virus-related hepatocellular 
carcinoma, as determined using RNA-seq: a) The percentage of whole immune cells in PPV carriers and non-carriers 





Figure 2-14. Family cancer history of patients with virus-related hepatocellular carcinoma for PPV carriers 
and non-carriers  
Odds ratios (ORs) were calculated at the 95% confidential interval level by the Fisher Exact test. Higher ORs indicate 
an increased cancer incidence in the family history of PPV carriers. Statistical significance is indicated in red (P 

































Impact of gender on PPV-bearing hepatocellular carcinoma 
To investigate the potential for gender bias in the immune surveillance 
of cancer cells, we performed DEG analysis segregated by gender for 
HBV-infected hepatocellular carcinoma patients, the most relevant 
disease in the above analysis. Hierarchical clustering was performed 
using the 163 DEGs identified previously during analysis to determine 
whether these were well-reflected in PPV-bearing cancer in both men 
and women. This analysis revealed that hierarchical clustering more 
accurately reflects PPV-carrier status in female HBV patients than in 
male HBV patients. In addition, gene set analysis identified two KEGG 
pathways (Mineral absorption, P<0.001, and p53 signaling pathway, 
P=0.01) that were significantly segregated by PPV-carrier status in 
women with HBV-related hepatocellular carcinoma, and interestingly, of 
these, the p53 pathway was down-regulated. Conversely, although 149 
genes were found to be differentially expressed in men with HBV-related 
hepatocellular carcinoma, specific pathways associated with these genes 
were not detected (Figure 2-15-a,b). To verify whether the DEG result of 
the TP53 pathway was an error, three cases and six control groups were 
randomly selected and subjected to DEG analysis 30 times. As a result 





Figure 2-15. DEG analysis by gender in Japanese hepatocellular carcinoma patients  
a) Hierarchical clustering of RNA expression profiles in female patients with HBV-related liver cancer is shown in 
the left panel, and the TP53 signaling map from KEGG pathway analysis is shown on the right. Green shading 
indicates down-regulated gene expression. b) Hierarchical clustering of RNA expression profiles in male patients 























External validation of the clinical significance of PPVs carrier status 
using targeted sequencing  
To verify the clinical significance of the 114 PID-related genes, we 
measured PPV status in an external cohort of 1,667 Korean patients with 
four types of cancer. Specifically, we analyzed the association between 
the age of cancer onset and PPV-carrier status in subjects with bladder 
cancer or liver cancer. For this analysis, we considered mutations found 
in >1% of the cohort as Korean-specific SNPs, and excluded these 
mutations from the test. 
The hepatocellular carcinoma cohort consisted of a total of 463 patients: 
401 with HBV-associated liver cancer (n=322 male, n=79 female), 61 
with HCV-associated liver cancer (n=44 male, n=17 female), and one 
subject with both HBV and HCV. We found that the age of onset for PPV 
carriers in the overall cohort tended to be lower, as compared to non-
carriers (median age: 57 for PPV carriers vs. 59 for PPV non-carriers; 
P=0.05). PPV status also appears to have a greater effect on age of onset 
in patients with HBV-related hepatocellular carcinoma (median age: 57 
for PPV carriers vs. 59 for PPV non-carriers; P=0.05), than in patients 
with HCV-related hepatocellular carcinoma (median age: 62 for PPV 
carriers vs. 67 for PPV non-carriers; P=0.35, Figure 2-17-a).  
Analysis of the association between age of onset and PID gene 
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immune pathology classification revealed that similar to our previous 
findings from the Pan-Cancer cohort, decreased age of onset was 
significantly associated with PPVs in “Predominantly antibody 
deficiency” genes (P=0.01, Figure 2-17-b). In female patients in 
particular, cancer development in PPV carriers was 12 years earlier than 
non-carriers, implying that immune surveillance has a gender-specific 
impact (median age: 52 for carriers vs. 64 for non-carriers; P<0.01, 
Figure 2-17-c). Further, the age of cancer onset in women with HBV-
related hepatocellular carcinoma was also significantly decreased 
(median age: 51 for carriers vs. 62 for non-carriers; P=0.01, Figure 2-17-
d). Notably, although age of onset did not show a statistically significant 
association with PPV-carrier status in the LIRI-JP subset of the Pan-
Cancer cohort, the trends were consistent for female subjects (mean 
onset age for women with HBV-associated liver cancer: 57 vs. 59, and 
mean onset age for women with HCV-associated liver cancer: 67 vs. 70; 
Figure 2-16). 
When PID genes were classified by immune pathology, we found 
that PPV carriers in “CID with associated or syndromic features” and 
“Predominantly antibody deficiencies” categories show reduced age of 
cancer onset, consistent with our previous results. Among these 
classifications, PPVs in the ATM gene in “CID with associated or 
syndromic features” and the TNFRSF12B gene in “Predominantly 
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Figure 2-16. Age of onset for HBV/HCV-related liver cancer by 
gender  
The points represent the age of cancer onset for each individual. The 
lines connect the mean age of onset in PPV carriers and PPV non-carriers 
and are colored by gender (red = female and blue = male).  
 
Figure 2-17. Association between the age of cancer onset and PPV-
carrier status in the Korean liver validation cohort  
a) The overall age of onset in PPV carriers and non-carriers is graphed 
on the left. Graphs on the right show age of onset for HBV-related and 
HCV-related liver cancer in PPV carriers and non-carriers. b) Age of 
onset in PPV carriers in each of the seven groups of PID genes, classified 
by immune pathology is shown. c) The graph on the left shows the age 
of onset in male and female PPV carriers and non-carriers. Graphs on the 
right show age of onset in PPV carriers, grouped by gender, in each of 
the seven groups of PID genes, classified by immune pathology. d) Age 
of onset in PPV carriers and non-carriers grouped by gender and disease 








































The Mendelian genetic disease has long been known to occur in children; however, recent 
cases of adult-onset Mendelian genetic disease have also been reported, such as with adult 
Gaucher disease (Guimaraes et al., 2003). This suggests that mild carriers with inherited 
genetic mutations, who do not develop severe disease in childhood, can survive until 
adulthood with partially defective gene function. From an immunological perspective, in 
many cases, these mild carriers are expected to experience a decline of immune 
surveillance, which may later contribute to the development of cancer.  
In this study, we screened a cancer patient cohort and a normal control cohort, 
both of which contained a population of individuals with undiagnosed PID, and found 
that even individuals who are not diagnosed with severe disease can harbor PID-
associated germline mutations. Moreover, using these large-scale WGS datasets, we 
uncovered underlying associations between mild carriers of PID and increased cancer risk. 
Both liver and bladder cancer showed increased prevalence and decreased age of cancer 
onset in PPV carriers vs. non-carriers for 114 PID-associated genes, suggesting that 
immune surveillance plays an important role in cancer development of the liver and 
bladder.  
The critical role of liver function in immune defense against various microbes and 
toxins is well-known. For example, the liver is required for immunological surveillance 
of the massive antigen load in the gastrointestinal tract, and it is involved in the systemic 
inflammatory response, induction of immunological tolerance, and destruction of 
activated lymphocytes. Thus, this organ plays essential roles in the first line immune 
defense against invading pathogens, the modulation of liver injury, and the recruitment of 
circulating lymphocytes (Racanelli and Rehermann, 2006). The role of the liver as an 
immunological organ is evidenced by the fact that approximately one-fourth of patients 
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with PID have some form of accompanying liver failure, with CID and common variable 
immunodeficiency (CVID) being the most common PIDs associated with liver disease 
(Rodrigues et al., 2004). CID is a complex immunodeficiency disease with various 
syndromes (here classified as “CID with associated or syndromic features”), and CVID 
is a condition associated with defects in overall antibody production (classified here with 
“Predominantly antibody deficiencies”).  
Our observed association between bladder cancer and immune system function 
can be explained by epidemiological observations in CVID Patients. Consistent with our 
findings, it was previously found that the incidence of bladder cancer in patients with 
CVID was around 4-fold higher than in those without CVID (Vajdic et al., 2010). Here, 
we found that CID and CVID were two of the most frequently found classifications and 
were the main determinants of clustering. In addition, liver cancer patients with PPVs in 
genes associated with CID and CVID developed cancer significantly earlier compared 
with wild-type liver cancer patients. Moreover, CID and CVID showed similar tendencies 
in our external validation cohort, strongly affirming our findings.  
CID with associated or syndromic features includes nine pathogenic features: 
congenital thrombocytopenia, DNA repair defects, immuno-osseous dysplasia, thymic 
defects with additional congenital anomalies, hyper-IgE syndromes, dyskeratosis 
congenita (DKC), defects of vitamin B12 and folate metabolism, anhidrotic ectodermal 
dysplasia, and others (Bousfiha et al., 2018). Among these, most defective genes that have 
been identified in CID are involved in DNA repair, including ATM, which was frequently 
found in our analysis. This gene is known to function in DNA repair, but it is also 
associated with various immunodeficiency symptoms, such as telangiectasia, pulmonary 
infections, and decreased IgA, IgE, and IgG subclasses (Lumsden et al., 2004; McGrath-
Morrow et al., 2010; McKinnon, 2004). In addition, an elevated prevalence of ATM 
germline mutations in cancer is known to increase the incidence of breast, gastric, and 
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colorectal cancer (Huang et al., 2015; Tavera-Tapia et al., 2017; Thompson et al., 2005). 
Loss of ATM also decreases levels of hepatocellular apoptosis and fibrosis in a high-fat 
diet-induced mouse model of non-alcoholic fatty liver disease, suggesting that this gene 
may play an important role in liver cancer (Daugherity et al., 2012). Based on these 
findings, we speculate that the mechanistic association between ATM and carcinogenesis 
detected in this study is due to the loss of its DNA repair function. However, due to the 
fact that ATM is also involved in various immunodeficiency diseases, it is possible that 
its effect on immune function also contributes to carcinogenic mechanisms.  
Another notable classification detected in this study, “Predominantly antibody 
deficiencies,” is composed of two immunological pathologies, including 
hypogammaglobulinemia and other antibody deficiencies (Bousfiha et al., 2018). A direct 
association between predisposing germline mutations in the TNFRSF13B gene and cancer 
development has not yet been established. However, TNFRSF13B deficiency is known to 
play a direct role in hypogammaglobulinemia, and the epidemiologic observation of 
elevated cancer development in patients with hypogammaglobulinemia has also been 
reported (Leone et al., 2018; Mohammadi et al., 2009).  
We further found that the elevated cancer incidence associated with PID was 
significantly affected by gender for HBV-related liver cancer. This phenomenon is 
believed to arise from differences in immune surveillance due to gender bias in various 
immune-related genes that are linked to hormones or the X-chromosome (Ellegren and 
Parsch, 2007; Fish, 2008; Oertelt-Prigione, 2012). In addition to genetic factors, 
carcinogenic chemical exposures are also considered to be one of the main causes of this 
gender bias. Generally, men are more exposed to carcinogenic chemicals, such as alcohol 
and tobacco, than women. In addition to differences in the frequency of physical 
exposures, Kadekar et al. found that men had a higher risk of cancer development from 
exposure to carcinogenic chemicals (Kadekar et al., 2012). Thus, the effect of genetic 
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factors on cancer in men is blurred, suggesting a possible reason that women were found 
to be more likely to develop cancer due to genetic factors. 
We also performed immune cell milieu analysis using RNA-seq data from viral-
associated hepatocellular carcinoma and found that intra-tumor infiltration of follicular 
helper T (Tfh) cells and regulatory T (Treg) cells were altered in PPV-bearing vs. PPV-
free tumors. Tfh cells represent a distinct subset of CD4+ T cells that specialize in 
providing help to B lymphocytes and are involved in infectious diseases, allergy, and 
autoimmunity. A strong positive correlation has been detected between prognosis and Tfh 
cells for several cancers, including breast and colorectal cancer, thus providing strong 
evidence these cells play a role in cancer immunity (Bindea et al., 2013; Gu-Trantien et 
al., 2013). Treg cells, which are characterized by expression of the master regulatory 
transcription factor, FOXP3, are a highly immunosuppressive subset of CD4+ T cells that 
maintain immune homeostasis. Critically, these cells can interrupt immune surveillance 
against cancer in healthy individuals, prevent the development of effective antitumor 
immunity in tumor-bearing patients, and promote tumor progression (Shitara and 
Nishikawa, 2018). Thus, the differences in tissue infiltration observed for both immune 
cell subsets in PPV-bearing vs. PPV-free tumors can be explained by PID-induced 
mechanisms of tumor development.  
Of note, inherited genetic mutations have been shown to affect cancer 
development in those under 40; however, their role in cancer development in those around 
the age of 50 has not been demonstrated. Nevertheless, identifying the relationship 
between suspected cancer-predisposing PID-associated mutations is crucial for cancer 
prevention and the development of enhanced therapeutic approaches. In particular, we 
note that immunoglobulin replacement therapy is a standard treatment for PID, and it can 
be used as a prophylactic immune therapy for patients who are expected to have a high 
incidence of cancer caused by PID (Krivan et al., 2017).  
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In conclusion, this study presents a comprehensive link between germline 
mutations in PID-associated genes and cancer, which advances our understanding of both 
immune surveillance and the mechanisms by which cancer is induced by PID. With this 
information, it may be possible not only to treat cancer, but also to develop aggressive 
prophylactic treatments that can replace surgical resection and are unlikely to involve 
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서론: 이전의 암 관련 생식선 돌연변이 연구는 TP53, APC, BRCA2, NF1, 
PMS2 및 RB1과 같은 종양 억제 유전자에 집중되어 연구 되어 왔다. 종양 
억제 유전자의 경우 병원성 돌연변이의 질병 침투도가 높기 때문에 연구가 
용이하여 많은 연구자로 하여금 수행되었다. 이 때문에 암 관련 생식선 연구
는 종양 억제 유전자에 초점을 맞추었고 이러한 이유로 종양 억제 유전자 
이외의 유전자의 생식선 돌연변이의 역할은 여전히 불분명하다. 그러나, 종
양 발달에 영향을 미치는 비 종양 억제 유전자의 존재 가능성은 무시할 수 
없다. 생식선 돌연변이로 존재하는 이러한 비 종양 억제 유전자에 의한 종양 
형성의 메커니즘은 종양억제 유전자의 종양 발달메커니즘과 다른 방식으로 
종양생성에 기여할 것으로 생각된다. 이 연구에서는, 비 종양 억제 유전자의 
생식선 돌연변이의 두 가지 다른 유형에 대해 논의 하고자 한다. 첫 번째는 
AML 환자의 종양 유전자(Oncogene)의 생식선 돌연변이이고, 두 번째는 
선천성 면역 결핍 유전자 돌연변이와 종양 위험 사이의 상관 관계이다. 
연구방법: 서울대병원을 내원한 76명의 급성골수성백혈병 환자의 엑솜유전
체 데이터가 종양 유발 유전자(Oncogene)의 생식세포 돌연변이 분석에 사
용되었다. 2566명의 ICGC 전장 유전체 데이터가 선천성 면역 결핍 유전자
와 암 발생의 상관관계를 확인하는데 사용되었으며, 2504명의 1000 게놈 
프로젝트 전장 유전체 데이터가 비교 군으로 사용되어 비교 분석 되었다.  
결과: 급성골수성백혈병의 발병을 증가시키는 종양 유발 유전자의 생식세포
돌연변이 분석을 위해 FLT3 유전자를 확인 하였다. 76명의 급성골수성백혈
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병 환자에서 4개 좌위의 FLT3 생식세포 돌연변이가 발견되었으며 
p.D358V 좌위에 해당하는 돌연변이가 급성골수성백혈병 발병을 증가시키는 
것이 확인 되었다. 또한 이 돌연변이를 가지고 있는 환자의 경우 좋지 않은 
예후를 보였다.  
선천성 면역결핍질환의 경우 선천성 면역결핍 질환 유전자는 암 발병을 1.5
배 증가 시켰다. 특히 7개 임종에서 암 위험이 증가하였으며 방광암과 간암
의 경우 선천성 면역결핍 질환 유전 변이를 보유한 암환자의 암 발병이 유
의하게 일찍 발병하는 것이 확인 되었다.  
결론: 우리는 이 논문에서 전에 밝혀지지 않은 두가지 종류의 생식세포 돌연
변이와 암 발병위험간의 상관관계를 밝혔다. 첫번째 생식선 돌연변이 유전자
는 종양 유전자로 알려져 있는 FLT3돌연변이 이다. 생식선 돌연변이로 존
재하는 FLT3의 경우 종양세포의 세포분열을 무한정 촉진 시키는 FLT3 체
세포 돌연변이와는 다르게 FLT3기능 저하를 유도하고 대안 세포 신호전달
계를 활성 시켜 종양세포의 발달에 기여하는 것으로 판단된다. 두번째 생식
선 돌연변이는 선천성 면역 결핍 질환과 관련된 유전자와의 상관관계이다. 
선천성 면역결핍과 관련된 유전자의 결핍은 종양 유전자 혹은 종양 억제 유
전자들 처럼 직접적인 세포 분열을 촉진 하지 않지만, 면역 감시 효과의 저
하로 인해 종양 발생을 촉진 하는 것으로 판단 된다.  
이 논문에서 확인된 생식세포 돌연변이뿐만 아니라 밝혀져야 하는 더 많
은 알려지지 않은 생식세포 돌연변이가 존재할 것으로 예상된다. 이와 같은 
노력은 치료 후 재발하는 암을 극복하기 위한 예방적 치료법을 개발하는데 
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